Detailed dose evidence documented for Exenatide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
The entries summarize the cited US FDA labels for the named exenatide products and type 2 diabetes indications.
Byetta: Initiate 5 mcg SC BID within 60 min before morning and evening meals (≥6 h apart). Increase to 10 mcg BID after 1 month. Subcutaneous injection in abdomen, thigh, or upper arm.
Bydureon: 2 mg SC once weekly, any time of day, with or without meals. Reconstitute microspheres in diluent before injection. Bydureon BCise autoinjector (same dose, prefilled).
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Studies evaluated Bydureon 0.8, 2.0 mg QW; only 2.0 mg was approved.
No studied regimen exceeded 10 mcg BID for Byetta or 2 mg QW for Bydureon.
Not established
What is not established
No established or recommended human dose for weight management in the absence of T2D.
Safety and efficacy of exenatide as monotherapy (all phase 3 trials were add-on).
Pediatric dosing after FDA review (2021) found insufficient evidence.
Efficacy after market discontinuation (2024); availability is limited to existing supply or international procurement.